The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

The trial is aimed at assessing long-term efficacy as well as safety of the therapy in 150 chronic HDV patients.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Gilead Sciences adds $11B to its U.S. investment plan, boosting manufacturing, R&D, and job creation. Read more here.

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the ...

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.